Lyme disease, caused by the spirochete Borrelia burgdorferi, is the most common vector-borne disease in the United States and Europe. The spirochetes are transmitted from mammalian and avian reservoir hosts to humans via ticks. Following tick bites, spirochetes colonize the host skin and then disseminate haematogenously to various organs, a process that requires this pathogen to evade host complement, an innate immune defence system. CspZ, a spirochete surface protein, facilitates resistance to complement-mediated killing in vitro by binding to the complement regulator, factor H (FH). Low expression levels of CspZ in spirochetes cultivated in vitro or during initiation of infection in vivo have been a major hurdle in delineating the role of this protein in pathogenesis. Here, we show that treatment of B. burgdorferi with human blood induces CspZ production and enhances resistance to complement. By contrast, a cspZ-deficient mutant and a strain that expressed an FH-nonbinding CspZ variant were impaired in their ability to cause bacteraemia and colonize tissues of mice or quail; virulence of these mutants was however restored in complement C3-deficient mice. These novel findings suggest that FH binding to CspZ facilitates B. burgdorferi complement evasion in vivo and promotes systemic infection in vertebrate hosts.
infection with Lyme borreliae can result in long-lasting and debilitating symptoms including arthritis, carditis, and neuroborreliosis (Steere et al., 2016) . Thus, dissemination and systemic infection require spirochetes to survive in the bloodstream of their different hosts (Radolf, Caimano, Stevenson, & Hu, 2012) .
Complement is one of the key host innate immune defence mechanisms (Meri, 2016; Zipfel & Skerka, 2009 ). In general, complement can be activated on the surface of invading pathogens by the classical, lectin, and/or alternative pathways. The classical pathway is initiated on pathogens when antibodies bind to target antigens and engage the C1 complex. The lectin pathway is activated when recognition molecules (mannan binding lectin, collectins, or ficolins) bind to select carbohydrates. The alternative pathway is initiated when activated C3b binds to the pathogen surface. Activation of all three pathways leads to the formation of C3 convertases (C4b2a by the classical and lectin pathway or C3bBb by the alternative pathway), and further activation and deposition of C3b on C3 convertases lead to the formation of C5 convertases. These multiprotein complexes ultimately promote the release of proinflammatory peptides, the deposition of opsonins (C3b and iC3b), and insertion of the pore-forming membrane attack complex (MAC; Merle, Church, Fremeaux-Bacchi, & Roumenina, 2015; Merle, Noe, Halbwachs-Mecarelli, Fremeaux-Bacchi, & Roumenina, 2015; Zipfel & Skerka, 2009) . Complement regulators such as factor H (FH) and FH-like protein 1 (FHL-1, the alternatively spliced form of FH) bind to C3b to promote its degradation into iC3b (Sjoberg, Trouw, & Blom, 2009; Zipfel & Skerka, 2009 ) and prevent excessive complement activation and host cell damage in the absence of pathogens or tissue injury.
Pathogens have developed multiple mechanisms to escape killing by complement (Lambris, Ricklin, & Geisbrecht, 2008) . One such mechanism is the production of complement-binding proteins to block the formation of complement complexes (Blom, Hallstrom, & Riesbeck, 2009; Kraiczy, 2016a; Marcinkiewicz, Kraiczy, & Lin, 2017; Meri, 2016) . Another mechanism is to express complement regulatorbinding proteins, which recruit host complement regulators to the cell surface to degrade active complement complexes Meri, 2016) . For example, Lyme borreliae produce OspC and BBK32, which, respectively, bind C4b and C1q to inhibit complement (Caine et al., 2017; Garcia, Zhi, Wager, Hook, & Skare, 2016) . This pathogen also produces at least five distinct complement regulator-acquiring surface proteins (CRASPs): CspA (CRASP-1), CspZ (CRASP-2), ErpP (CRASP-3), ErpC (CRASP-4), and ErpA (CRASP-5; Kraiczy & Stevenson, 2013) . These proteins bind to FH and/or FHL-1 (CspA and CspZ only) to inhibit the alternative pathway (Kraiczy & Stevenson, 2013) .
One of these FH-binding CRASPs, CspZ, promotes survival of otherwise serum-sensitive, nonpathogenic Lyme borreliae in human serum when overexpressed in these strains (Hartmann et al., 2006; Siegel et al., 2008) . This protein is produced during mouse infection but not when the spirochetes reside in unfed or feeding ticks , suggesting a role of CspZ in providing bacteria the ability to survive in the hosts. However, a cspZ-deficient strain is fully infectious via needle infection (Coleman et al., 2008) . Additionally, when mice were subcutaneously inoculated with a library of B. burgdorferi mutants carrying transposon insertions, mutants with transposon insertions in cspZ displayed only minor defects in colonization of mice (T. Lin et al., 2012) . Interestingly, B. burgdorferi produces extremely low levels of CspZ when cultivated in vitro .
This finding raises a possibility that low production of CspZ in in vitro cultivated wild-type (WT) B. burgdorferi does not permit elucidation of differences in serum survival or infectivity between the WT and the cspZ-deficient mutant strain.
Spirochetes produce distinct protein profiles when cultivated in different conditions in vitro or while infecting vertebrate animals (Brooks, Hefty, Jolliff, & Akins, 2003; Hyde, Trzeciakowski, & Skare, 2007; Ojaimi et al., 2003; Revel, Talaat, & Norgard, 2002; Seshu, Boylan, Gherardini, & Skare, 2004; Tokarz, Anderton, Katona, & Benach, 2004) . Incubating B. burgdorferi with mammalian blood simulates the conditions in hosts that leads to upregulation of genes that are normally expressed when spirochetes are in vertebrate hosts (Tokarz et al., 2004) . In fact, blood treatment of spirochetes has been used to delineate the roles of several spirochete genes in vivo (Caine & Coburn, 2015; Caine et al., 2017; Y. P. Lin et al., 2015; Moriarty et al., 2012; Norman et al., 2008) . Therefore, we hypothesized that blood treatment of spirochetes would enhance the production of CspZ thereby permitting examination of this protein in facilitating serum survival and infectivity in diverse hosts. In this study, we tested this hypothesis and elucidated a novel role for CspZ-FH interactions in bacterial pathogenesis in vivo.
| RESULTS

| Treating B. burgdorferi with human blood enhances CspZ production
To define CspZ's role in vitro and in vivo, we obtained WT infectious B. burgdorferi B31-A3 and its isogenic cspZ-deficient mutant, B31-A3ΔcspZ (Coleman et al., 2008) . This mutant strain carrying shuttle vector pKFSS (B31-A3ΔcspZ-V) or complemented with a plasmid encoding WT cspZ was generated. We also constructed a shuttle vector encoding this gene's promoter from B. burgdorferi strain B31-A3 to drive cspZ-Y207A/Y211A, which produces the point mutant of CspZ defective in FH-binding activity (Siegel et al., 2008) . This plasmid was transformed into B31-A3ΔcspZ as to generate complemented strain as a negative control. Note that CspZ-Y207A/Y211A was chosen to specifically eliminate FH binding; a previous study showed that CspZ-Y207A/Y211A binds to neither human nor mouse FH (Marcinkiewicz et al., 2018; Siegel et al., 2008) . This is because a hydrogen bond between FH and tyrosine-207 of CspZ is abolished in this mutant protein (PDB#6ATG; http://www.rcsb.org/structure/ 6ATG). We also found that CspZ-Y207A/Y211A does not bind to FH from Coturnix quail, the avian model of LD (Isogai et al., 1994) , whereas WT CspZ bound ( Figure S1 bottom and Table 1 ). Further, recombinant CspZ-Y207A/Y211A protein maintained its secondary structure, similar to the recombinant CspZ ( Figure S2 ), and displayed similar levels of fibronectin, laminin, and plasminogen binding as WT CspZ (Hallstrom et al., 2010 ; Figure S3 and Table S1 ).
Hypothesizing that CspZ production is upregulated by vertebrate animals' blood that simulates the host conditions, we first treated WT B. burgdorferi strain B31-A3 with human blood, and cspZ expression was quantitated by reverse transcription polymerase chain reaction (qRT-PCR). Mid-log phase B31-A3 were incubated with that blood for 48 hr as previously described (Tokarz et al., 2004) . We found that untreated and blood-treated spirochetes expressed similar levels of recA, a constitutively expressed gene ( Figure 1a ). Untreated B. burgdorferi expressed low but detectable of cspZ, consistent with previous reports (Coleman et al., 2008; Hartmann et al., 2006; Rogers, Abdunnur, McDowell, & Marconi, 2009;  Figure 1a ). Blood-treated B. burgdorferi expressed 4.1-fold greater levels of cspZ compared with untreated spirochetes (Figure 1a) . We then sought to determine if increased cspZ expression translates to greater amounts of CspZ on the spirochete surface using flow cytometry (Figure 1b) . The periplasmic flagellin protein FlaB and the FH-binding protein CspA were used as controls. As expected, the production of FlaB was detectable in methanol-permeabilized but not in unpermeabilized B. burgdorferi cells, consistent with the periplasmic location of this protein (Kumru, Schulze, Slusser, & Zuckert, 2010; Limberger, 2004; Figure 1c) . The levels of FlaB were indistinguishable between untreated and bloodtreated cells (Figure 1c ). The production of CspA was indistinguishable between permeabilized and unpermeabilized cells, in agreement with CspA's surface localization (Figure 1c ; Kraiczy et al., 2004) . Consistent to previous work Bykowski et al., 2007; Tokarz et al., 2004) , CspA levels decreased 3.3-fold in blood-treated com- Note. All values represent the mean ± SEM of three experiments determined by enzyme-linked immunosorbent assay. GST, Glutathione S-transferase; n.b., No binding activity was detected; GST was included as a negative control.
FIGURE 1
The surface production of CspZ was enhanced in human blood-treated Borrelia burgdorferi compared with untreated spirochetes. Approximately 5 × 10 6 cells of the B. burgdorferi strain B31-A3 were cultivated in BSK-II medium with or without ("Untreated") 5% blood ("Blood") for 48 hr. (a) RNA from blood-treated or untreated spirochetes was extracted. The expression levels of cspZ, the constitutively expressed genes 16s rRNA, and recA were determined using quantitative reverse transcription polymerase chain reaction. The expression levels of recA (control) and cspZ are presented by normalising to the expression levels of the gene encoding 16s rRNA. Each bar represents the mean of four independent determinations ± SEM. The asterisk ("*") indicates significant differences (P < 0.05; Mann-Whitney test) in the normalised expression levels of cspZ in blood-treated spirochetes relative to that of untreated spirochetes. (b) Representative histograms of flow cytometry analysis showing the levels of CspZ surface production to blood-treated or untreated spirochetes. The shaded histograms are derived from untreated or blood-treated spirochetes incubated only with Alexa 647-conjugated goat anti-mouse IgG as control. (c-f) The production of FlaB (negative control), CspA, or CspZ on the surface of blood-treated or untreated spirochetes was detected by flow cytometry. The mean fluorescence index ("MFI") represents the production levels of FlaB, CspA, or CspZ in unpermeabilized (filled bars) or methanol-permeabilized (opened bars) (c) B. burgdorferi strain B31-A3, (d) B31-A3ΔcspZ harbouring the vector pKFSS-1 ("B31-A3ΔcspZ/Vector"), or (e) this cspZ mutant strain producing CspZ ("B31-A3ΔcspZ/pCspZ") or (f) CspZ-Y207A/Y211A ("B31-A3ΔcspZ/pCspZ-Y207A/Y211A"). Each bar represents the mean of four independent determinations ± the standard deviation. The asterisk ("*") indicates significantly different protein production (P < 0.05 by KruskalWallis test with Dunn's multiple comparison) between blood-treated and untreated indicated B. burgdorferi strains. Note that the production of FlaB, CspA, or CspZ among different spirochete strains when these strains were in blood-treated or untreated conditions is no different (P > 0.05 by Kruskal-Wallis test with Dunn's multiple comparison) Dowdell et al., 2017; Hartmann et al., 2006) . Strikingly, we observed a 5.3-fold enhancement of CspZ production in human blood-treated strain B31-A3 compared to that protein's production in the same strain with no blood treatment. (Figure 1b,c) . Further, we incubated blood with B31-A3ΔcspZ-V or B31-A3ΔcspZ producing WT cspZ or cspZ-Y207A/Y211A. Similarly, the strain B31-A3ΔcspZ producing WT cspZ or cspZ-Y207A/Y211A exhibited enhanced CspZ production, whereas these strains and the B31-A3Δ-cspZ-V displayed decreased CspA production after blood treatment (Figure 1d-f) . Note that all these strains displayed indistinguishable levels of viability and generation time in either untreated or bloodtreated conditions. These results suggest that spirochete growth is not altered, and there is no difference among strains regarding to viability after blood treatment ( Figure S4 and Tables S2 and S3 ). Taken together, these findings indicate that blood treatment induces CspZ production and downregulates CspA production in the B. burgdorferi strains that encode the genes to produce these proteins. strain B313 was also included as a negative control because this strain lacks the plasmids encoding CspZ and CspA (Hallstrom et al., 2013 ).
2.2
We found that the level of these hosts' FH bound by B31-A3 and B31-A3ΔcspZ-V was greater than that by B313 but undistinguishable between each other ( Figure S5 ). These findings indicated that in the absence of blood treatment, FH binding to B31-A3 and B31-A3Δ-cspZ-V was similar. To enhance CspZ production in the WT isolate and downregulate CspA production in both WT and mutant, we treated these strains with human blood and assessed binding of human, mouse, and quail FH to each of these spirochete strains. As expected, B313 bound nearly undetectable levels of these hosts' FH ( Figure 2 ; Hart, Nguyen, et al., 2018; Hartmann et al., 2006) . Consistent with previous observations (Hart, Nguyen, et al., 2018; Kenedy, Vuppala, Siegel, Kraiczy, & Akins, 2009; McDowell et al., 2003) , B31- 
| CspZ binding to FH facilitates blood-treated B. burgdorferi to survive in serum
We aimed to determine CspZ's role in promoting spirochete survival in serum. The WT strain B31-A3 and B31-A3ΔcspZ-V were incubated with human or quail serum, or negative control sera that were not expected to kill bacteria (C3-depleted human serum or heatinactivated human or quail serum) for 4 hr. Mouse serum was not tested because mouse complement is highly unstable ex vivo (Caine & Coburn, 2015; Lachmann, 2010; Marcinkiewicz et al., 2017; Ristow et al., 2012) . Consistent with previous findings (Coleman et al., 2008) , we found that nearly 100% of the WT strain B31-A3 and B31-A3Δ-cspZ-V survive in human, quail, and negative control sera ( Figure S7 ).
We then treated the WT strain B31-A3 or B31-A3ΔcspZ-V with human blood to enhance expression of cspZ prior to incubation with sera. Over 75% of the WT strain B31-A3 survived in active ( 
| FH binding to CspZ confers bacteraemia and tissue colonization of blood-treated B. burgdorferi
We next asked whether CspZ-mediated FH binding promotes infectivity in mice. Subcutaneous needle infection of spirochetes with the dose close to ID 50 (the dose that infects 50% of animals) often reveals subtle in vivo phenotypes conferred by spirochete genes that are expressed in hosts (Blevins, Hagman, & Norgard, 2008; Hyde et al., 2011; Seshu et al., 2006; Shi, Xu, Seemanaplli, McShan, & Liang, 2008; Weening et al., 2008) . We thus introduced 10 3 cells of WT strain B31-A3 or B31-A3ΔcspZ-V into BALB/c mice (the ID 50 of strain B31-A3 is~10 . Each bar represents the mean of three independent determinations ± SEM. Significant differences (P < 0.05 by Kruskal-Wallis test with Dunn's multiple comparison) in the levels of FH binding relative to the strain B313 ("Φ"), the strain ΔcspZ/Vector ("*"), or between two strains relative to each other ("#") are indicated FIGURE 4 CspZ-mediated factor H-binding activity contributed to the survival of blood-treated spirochetes in human and quail serum. Human blood-treated Borrelia burgdorferi strain B31-A3, B31-A3ΔcspZ harbouring the vector pKFSS-1 ("B31-A3ΔcspZ/Vector"), or this cspZ mutant strain producing CspZ ("B31-A3ΔcspZ/pCspZ") or CspZ-Y207A/Y211A ("B31-A3ΔcspZ/pCspZ-Y207A/Y211A") was incubated for 4 hr with untreated (filled bars) or heat-inactivated ("Heat-treated," hatched bars) serum at a final concentration of 40%. These sera include (a) normal human serum, (b) C3-depleted human serum ("Human C3 − serum"), or (c) quail serum. The number of motile spirochetes was assessed microscopically. The percentage of surviving B. burgdorferi was calculated using the number of mobile spirochetes at 4 hr post incubation normalised to that immediately after incubation with serum. Each bar represents the mean of three independent determinations ± SEM. Significant differences (P < 0.05 by Kruskal-Wallis test with Dunn's multiple comparison) in the percentage of surviving spirochetes relative to the strain B31-A3ΔcspZ/Vector incubated with untreated serum ("*") or between two strains relative to each other ("#") are indicated FIGURE 3 CspZ-mediated factor H-binding activity decreased membrane attack complex (MAC) deposition on the surface of blood-treated Borrelia burgdorferi. Human blood-treated B. burgdorferi strain B313, B31-A3, B31-A3ΔcspZ harbouring the vector pKFSS-1 ("B31-A3ΔcspZ/Vector"), or this cspZ mutant strain producing CspZ ("B31-A3ΔcspZ/pCspZ") or CspZ-Y207A/Y211A ("B31-A3ΔcspZ/ pCspZ-Y207A/Y211A") was incubated with either PBS (negative control, data not shown) or serum from human or mouse at a final concentration of 20%. The bacteria were stained with a mouse anti-MAC monoclonal antibody aE11 (for spirochetes incubated with human serum), or a rabbit anti-MAC polyclonal IgG (for spirochetes incubated with mouse serum) followed by a goat anti-mouse IgG, or a goat anti-rabbit IgG, prior to flow cytometry analysis. (a) Representative histograms of flow cytometry analysis showing the deposition levels of mouse MAC on the surface of indicated Borrelia burgdorferi strains. (b) The deposition levels of human or mouse MAC on the surface of B. burgdorferi were measured by flow cytometry and presented as mean fluorescence index ("MFI"). Each bar represents the mean of three independent determinations ± SEM. Significant differences (P < 0.05 by Kruskal-Wallis test with Dunn's multiple comparison) in the deposition levels of MAC relative to the strain B313 ("Φ"), the strain B31-A3ΔcspZ/Vector ("*"), or between two strains relative to each other ("#") are indicated
In order to delineate the role of CspZ during the course of infection, we treated WT strain B31-A3 and B31-A3ΔcspZ-V with human blood to upregulate cspZ expression. BALB/c mice were then infected with blood-treated B31-A3 or B31-A3ΔcspZ-V. Bacteraemia triggered by the former strain was observed at 7 dpi but not at 14 dpi ( Figure 5 a). Colonization was detected for WT strain B31-A3 in all tested tissues at 7 and 14 dpi (Figure 5b -e). In contrast, the strain B31-A3Δ-cspZ-V induced sixfold less levels of bacteraemia at 7 dpi (P = 0.021; Figure 5a , left panel) and displayed 2,600-fold and ninefold lower spirochete burden at the inoculation site than the WT strain at 7 and 14 dpi, respectively (P < 0.05; Figure 5b ). The cspZ-deficient strain also exhibited a lower, although not statistically significant, level of colonization of the heart, bladder, and joints compared with the WT strain at 7 dpi ( A3ΔcspZ harbouring the vector pKFSS-1 ("B31-A3ΔcspZ/Vector"), or this cspZ mutant strain producing CspZ ("B31-A3ΔcspZ/pCspZ") or CspZ-Y207A/Y211A ("B31-A3ΔcspZ/pCspZ-Y207A/Y211A"). These mice were sacrificed at (left panel) 7 or (right panel) 14 days post infection ("dpi"). The spirochete burdens in the (a) Blood, (b) inoculation site of skin ("Inoc. Site"), (c) heart, (d) bladder, and (e) tibiotarsus joints were determined by quantitative polymerase chain reaction and normalised to 1 μg of total DNA. Shown are the geometric mean ± geometric standard deviation of 14 (blood from B31-A3-infected mice at 7 dpi), 15 (blood from B31-A3ΔcspZ/Vectoror B31-A3ΔcspZ/pCspZ-Y207A/Y211A-infected mice at 7 dpi), 12 (blood from B31-A3ΔcspZ/pCspZ-infected mice at 7 dpi), 6 (blood from B31-A3-infected mice at 14 dpi), 8 (tibiotarsus joints from B31-A3-infected mice), 16 (Inoc. Site from B31-A3-or B31-A3ΔcspZ/ pCspZ-infected mice at 14 dpi), 9 (bladder or heart from B31-A3-infected mice at 14 dpi), 7 (blood from B31-A3ΔcspZ/Vector-infected mice or bladder or heart from B31-A3ΔcspZ/pCspZ-infected mice at 14 dpi), or 10 (all others) mice per group. Significant differences (P < 0.05 by Kruskal-Wallis test with Dunn's multiple comparison) in the spirochete burdens relative to the strain B31-A3ΔcspZ/Vector ("*") or between two strains relative to each other ("#") are indicated. n.d.: not determined
| FH-binding activity of CspZ promotes spirochete colonization in quail
We aimed to test whether CspZ-mediated FH binding confers infectivity of B. burgdorferi in avian hosts such as the quail. We thus treated WT strain B31-A3 with human blood to enhance the production of CspZ, subcutaneously inoculated 10 6 cells of B31-A3 cells into quail, and determined bacterial burdens using qPCR in the blood and tissues.
We could not detect WT strain B31-A3 in the blood or any tested tissues at 3 dpi (detection limit: one bacterium per one microgram of DNA; Figure S9 ). Although we were still unable to detect spirochetes in the blood, liver, or heart at 7 dpi, spirochetes were detectable at the inoculation site and the brain at this time point (Figures 7 and S9 ). The viability of spirochetes in these tissues was verified microscopically after culturing the tissues collected from the quail at 7 dpi: Five out of six quail inoculation sites and brain tissues were culture positive.
We also subcutaneously infected quail with human blood-treated B31-A3ΔcspZ-V or this strain producing CspZ or CspZ-Y207A/ Y211A. At 7 dpi, the strain B31-A3ΔcspZ-V colonized the inoculation site and brain approximately fivefold to eightfold less, respectively, compared with WT strain B31-A3 (Figure 7 ). Ectopically producing CspZ in B31-A3ΔcspZ restored the colonization defects in these tissues (Figure 7 ), indicating that CspZ contributes to B. burgdorferi colonization at quail tissues. However, ectopic production of CspZ-Y207A/Y211A did not restore colonization levels in the inoculation site and brain (similar spirochete burdens to mutant B31-A3ΔcspZ-V; Figure 7 ). These results suggest that CspZ binds to FH to facilitate spirochetes to establish infection and promote dissemination in quail.
| DISCUSSION
B. burgdorferi, the causative agent of LD, produces at least 86 outer surface lipoproteins (Dowdell et al., 2017) . Although some of these proteins are produced in abundance, most are expressed at low levels when cultured in vitro and/or during murine infection (Kenedy, Lenhart, & Akins, 2012) , which have been hurdles in studying their roles in pathogenesis. Cultivating B. burgdorferi in specific conditions such as blood-supplemented growth media to induce the production of proteins of interest has been utilized to investigate the role of such proteins in vitro and in vivo (Kumar et al., 2015; Moriarty et al., 2012; Parveen & Leong, 2000; Zhi et al., 2015) . We used human blood to treat spirochetes and observed induction of CspZ (Figure 1 ) as this host's blood has been used as a host-simulated cue to alter the expression of spirochetes genes (Tokarz et al., 2004) . However, the molecular compositions of different animal species' blood differ (Hamdy, 1977; Sojka et al., 2013; Wickramasekara, Bunikis, Wysocki, & Barbour, 2008) , raising the possibility that enhanced cspZ expression is host blood-specific, which warrants further investigation. Additionally, human blood treatment of spirochetes followed by murine infection may not reflect to the nature life cycle of Lyme borreliae in mice. This concern could be eased by treating spirochetes with mouse blood prior to infection for future studies. Further, Tokarz et al. (2004) did not report an increased cspZ expression in spirochetes treated with human blood using a microarray, which could be due to the FIGURE 6 CspZ-mediated factor H-binding activity facilitated bacteraemia and tissue colonisation of blood-treated spirochetes by evading the mouse complement. BALB/c C3 −/− mice were subcutaneously infected with 10 3 cells of human blood-treated Borrelia burgdorferi strain B31-A3, B31-A3ΔcspZ harbouring the vector pKFSS-1 ("B31-A3ΔcspZ/Vector"), or this cspZ mutant strain producing CspZ ("B31-A3ΔcspZ/pCspZ") or CspZ-Y207A/Y211A ("B31-A3ΔcspZ/pCspZ-Y207A/Y211A"). The mice were sacrificed at (left panel) 7 or (right panel) 14 days post infection ("dpi"). The spirochete burdens in the (a) blood, (b) inoculation site of skin ("Inoc Site"), (c) heart, (d) bladder, and (e) tibiotarsus joints were determined by quantitative polymerase chain reaction and normalised to 1 μg of total DNA. Shown are the geometric mean ± geometric standard deviation of five (tibiotarsus joints from B31-A3ΔcspZ/pCspZ-Y207A/ Y211A-infected mice at 7 dpi) or six (all others) mice per group. There were no significant differences (P < 0.05 by Kruskal-Wallis test with Dunn's multiple comparison) in the spirochete burdens relative to the strain B31-A3ΔcspZ/Vector or between two strains relative to each other stringent criteria used to define the differential gene expression. resistance to digestion by these proteases (Coleman et al., 2008; Dowdell et al., 2017; Hartmann et al., 2006) . However, CspZ is eliminated when spirochetes are treated with pronase (Dowdell et al., 2017) , a protease isolated from Streptomyces griseus (Hiramatsu & Ouchi, 1963) . This finding indicates this protein's surface localization, consistent with our and previous observations using fluorescencebased methodologies Hartmann et al., 2006; Siegel et al., 2008 ; Figure 1b ,c,e,f).
We found that blood treatment is essential to demonstrate the CspZ-mediated FH-binding activity to confer spirochete survival in sera (Figure 4) . It is noteworthy that we count immotile cells as the indicator of cell death by dark-field microscopy, a method that has been commonly used to identify killed cells (Alitalo et al., 2001; Alitalo et al., 2005; Brooks et al., 2005; Kraiczy, Hunfeld, Peters, et al., 2000; McDowell et al., 2011; van Dam et al., 1997) . Furthermore, the lack of motility is the most apparent sign of complement-mediated bacterial killing, which allows determination of cell viability microscopically without the need for the extended duration of time to cultivate spirochetes. Further, the ability of pathogens to limit complement activation on their surface often correlates with their ability to survive in the bloodstream and cause systemic infection (Lambris et al., 2008; Roantree & Rantz, 1960) . For example, the B. burgdorferi outer surface protein BBK32 inhibits activation of the classical pathway and confers resistance to human serum (Garcia et al., 2016) . This protein also promotes spirochete survival in the mouse bloodstream and dissemination (Caine & Coburn, 2015; Hyde et al., 2011; Seshu et al., 2006) .
Similarly, B. burgdorferi produces OspC that inactivates both classical
and lectin pathways and contributes to early stages of bacteraemia (Caine et al., 2017; Caine & Coburn, 2015) . In this study, we treated a cspZ-deficient B. burgdorferi with blood to demonstrate this CspZ's ability, by evading complement, to promote bacteraemia and/or tissue colonization ( Figures 5 and 6 ). Note that this finding does not imply that CspZ facilitates spirochete survival in fed ticks during transmission as B. burgdorferi does not produce CspZ when it is in either post-molting flat nymphs or feeding nymphs . However, CspZ is produced at low levels in the biting site of skin after transmission . Therefore, in the case that a cspZ-deficient spirochete displays defect of infectivity in vertebrate hosts during transmission, CspZ's role should be dependent on the host environment such as skin. Further, B. burgdorferi has been shown to more efficiently spread to distal tissues in mice deficient of some complement proteins (e.g., C3 −/− or C1qα −/− mice) compared with WT mice (Lawrenz et al., 2003; Woodman et al., 2007; Zhi, Xie, & Skare, 2018) . Similarly, we observed increased spirochete burdens in the tissues of C3 −/− mice (Figure 6b site (Wilhelm, 1973) . This addresses our finding that spirochetes use the FH-binding activity of CspZ to establish infection at inoculation site (Figures 5b and 6b ).
FIGURE 7
CspZ-mediated factor H-binding activity promoted Borrelia burgdorferi colonisation in quail. Coturnix coturnix quail were subcutaneously infected with 10 6 cells of human blood-treated B. burgdorferi strain B31-A3, B31-A3ΔcspZ harbouring the vector pKFSS-1 ("B31-A3ΔcspZ/Vector"), or this cspZ mutant strain producing CspZ ("B31-A3ΔcspZ/pCspZ") or CspZ-Y207A/Y211A ("B31-A3ΔcspZ/pCspZ-Y207A/Y211A"). The quail were sacrificed at 7 days post infection ("dpi"). The spirochete burdens in the (a) inoculation site of skin ("Inoc. Site") and (b) brain were determined by quantitative polymerase chain reaction and normalised to 1 μg of total DNA. Shown are the geometric mean ± geometric standard deviation of 8 (B31-A3-infected quail), 14 (Inoc. Site from B31-A3ΔcspZ/pCspZinfected quail), 9 (brain from B31-A3ΔcspZ/pCspZ-infected quail), and 6 (all others) quail per group. Significant differences (P < 0.05 by Kruskal-Wallis test with Dunn's multiple comparison) in the spirochete burdens relative to the strain B31-A3ΔcspZ/Vector ("*") or between two strains relative to each other ("#") are indicated
In addition to mammals, birds also maintain Lyme borreliae as a reservoir host in the enzootic cycle (Brisson et al., 2012; Eisen & Eisen, 2018) . However, the molecular mechanisms of spirochete colonization and dissemination in this host remain unclear. This could be due to the cumbersome work of maintaining wild-caught birds and/or the inability to persistently infect some avian hosts with Lyme borreliae experimentally (Bishop, Khan, & Nielsen, 1994; Burgess, 1989; Ginsberg et al., 2005; Isogai et al., 1994; Kurtenbach et al., 1998; Olsen, Gylfe, & Bergstrom, 1996; Piesman, Dolan, Schriefer, & Burkot, 1996; Richter, Spielman, Komar, & Matuschka, 2000) . Among these avian species, Coturnix quail is capable of harbouring Lyme borreliae for at least 8 weeks after needle infection (Isogai et al., 1994) . Similar to previous findings (Isogai et al., 1994 ),
we did not detect spirochetes in the blood during infection ( Figure   S9 ), reiterating the inability of Lyme borreliae to induce high levels of bacteraemia in vertebrate animals (Steere et al., 2016) . Unlike a previous study detecting spirochetes in the liver and heart of Borrelia garinii-infected quail (Isogai et al., 1994) , we did not observe B. burgdorferi colonization at these sites, possibly reflecting strainspecific tissue tropism ( Figure S9 ; Craig-Mylius, Lee, Jones, & Glickstein, 2009; Jones et al., 2006; Wang, xvan Dam, Schwartz, & Dankert, 1999) . We found that CspZ-mediated FH-binding activity facilitates spirochete colonization at the quail inoculation site and brain, which reveals the role of a B. burgdorferi protein in promoting avian host competence at the first time ( Figure 7 ). Note that not every strain of Lyme borreliae species encodes CspZ (Kingry et al., 2016; Kraiczy, Skerka, Brade, & Zipfel, 2001; Rogers & Marconi, 2007) and allelic variations confer differential human FH/FHL-1-binding activity (Kraiczy et al., 2001; Kraiczy et al., 2008; Rogers et al., 2009 ). This raises the possibility that CspZ variants may determine host specificity of FH binding and determine the animals' competence to each strain (Bhide et al., 2005; Kraiczy, 2016b; . This could be further investigated using the quail and mouse as Lyme infection models established in this study. Such models can also be applied to study the role of additional proteins of B. burgdorferi or other pathogens that are induced during blood treatment in promoting infectivity. Gaining an understanding of the mechanisms of pathogen infectivity can permit further efforts to find treatments or vaccines to improve human health.
| EXPERIMENTAL PROCEDURES
| Ethics statement
All mouse experiments were performed in strict accordance with all provisions of the Animal Welfare Act, the Guide for the Care and 
| Mouse, quail, bacterial strains, and animal sera
Swiss Webster mice used to generate antiserum against CspZ and BALB/c mice were purchased from Charles River (Wilmington, MA) and Taconic (Hudson, NY), respectively. C3 −/− mice (C57BL/6) purchased from Jackson Laboratory (Bar Harbor, ME) were backcrossed for 11 generations into a BALB/c background. Mice were genotyped for the C3 alleles by PCR analysis of mouse tail DNA (Table S4) .
Coturnix coturnix quail were purchased from Cavendish Game Birds Farm (Springfield, VT). The Borrelia and Escherichia coli strains used in this study are described in Table 2 . All B. burgdorferi strains were 
B313
High-passage B. burgdorferi B31 missing lp5, lp17, lp21, lp25, lp28-1, lp28-2, lp28-3, lp28-4, lp36, lp38, lp54, lp56, cp9, cp32-4, cp32-6, cp32-8, cp32-9
Hallstrom et al.
B31-A3 Clone of B. burgdorferi B31 missing cp9
Elias et al. This study grown at 33°C in BSK-II complete medium supplemented with kana-
), streptomycin (50 μg ml ), or no antibiotics (Table 2) protein VlsE (Lawrenz et al., 1999) .
| Generation of recombinant CspZ proteins and antisera
The open reading frames lacking the putative signal sequences of bbh06 (cspZ) or encoding CspZ-Y207A/Y211A (CspZ with tyrosine-207 and tyrosine-211 replaced by alanine residues) from B. burgdorferi strain B31-A3 were amplified using listed plasmids and primers (Tables 2 and S4 ; Siegel et al., 2008) . Amplified fragments were engineered to encode a BamHI site at the 5′ end and a stop codon followed by a SalI site at the 3′ end. PCR products were sequentially digested with BamHI and SalI and then inserted into the BamHI and SalI sites of pGEX4T2 (GE Healthcare, Piscataway, NJ). The plasmids were sequenced and then transformed into E. coli strain BL21(DE3) (Wadsworth ATGC facility). The GST-tagged CspZ proteins were produced and purified by GST affinity chromatography according to the manufacturer's instructions (GE Healthcare, Piscataway, NJ). Antisera against CspZ were generated by immunising 4-week-old Swiss Webster mice with each of the CspZ proteins as described (Benoit, Fischer, Lin, Parveen, & Leong, 2011) .
| Quantitative RT-PCR and PCR
For qRT-PCR, RNA was extracted from B. burgdorferi strain B31-A3
using Direct-Zol RNA MiniPrep Plus Kit (Zymo Research, Irvine, CA), and contaminating DNA was removed using RQ1 RNase-Free DNase (Promega, Madison, WI). cDNA was synthesized from 1 μg of RNA using qScript cDNA SuperMix (Quanta Bioscience, Beverly, MA). The primers used for the quantification of 16s rRNA, cspZ, or recA expression are listed in Table S4 Hodzic, Feng, & Barthold, 2013; Morrison, Ma, Weis, & Weis, 1999 joint, and bladder of mice, or the inoculation site and brain of quail were used in qPCR using mouse nidogen or quail β-actin primers (Table S4 ; Hart, Yang, Pal, & Lin, 2018; Y. P. Lin et al., 2014) . As predicted, we detected 10 7 copies of the mouse nidogen or quail β-actin 
| Enzyme-linked immunosorbent assays
An enzyme-linked immunosorbent assay for FH, fibronectin, plasminogen, and laminin binding by CspZ proteins was performed as described (Y. P. Lin et al., 2009) . One microgram of BSA (negative control; Sigma-Aldrich, St. Louis, MO), quail FH previously purified from quail serum (Hart, Nguyen, et al., 2018) , the data were fitted with Equation (2) using GraphPad Prism software (GraphPad, La Jolla, CA). Table 2 ). The promoter region of cspZ from B. burgdorferi B31, 125 bp upstream from the start codon of cspZ, was also PCR amplified (Hartmann et al., 2006) , added with SphI and SalI sites at the 5′and 3′ ends, respectively, using primers listed in Table S4 . Promoter fragments were then inserted into the SphI and SalI sites of pKFSS-1 to drive the expression of cspZ and cspZ-Y207A/Y211A. Electrocompetent B. burgdorferi B31-A3ΔcspZ prepared as described (Samuels, 1995) was then transformed separately with at least 44 μg of each of the shuttle plasmids (Table 2) (Table S4 ). The plasmid profiles of these spirochetes were examined as described (Purser & Norris, 2000) to ascertain identical profiles between these strains and their parental strain B31-A3.
| Determination of the viability and generation time of spirochetes
To determine spirochete viability after blood treatment, B. burgdorferi strains were cultivated in triplicate in untreated or human bloodtreated conditions. After resuspending spirochetes in BSK-II medium without rabbit serum, they were stained for 15 min with 1× SYBR Green I (ThermoFisher) and 6 μM of propidium iodide (ThermoFisher) in 0.5% BSA in PBS as described (Feng, Wang, Zhang, Shi, & Zhang, 2014 ) was cultivated BSK-II medium without human blood in triplicate to determine the spirochetes' generation time. The concentration of the spirochetes was calculated microscopically in triplicate every 24 hr. We then calculated the generation time for each strain in exponential phase (G)
as previously described (Heroldova, Nemec, & Hubalek, 1998) .
| Flow cytometry
CspZ production, FH binding, and MAC deposition on spirochete surface were determined as described (Hart, Nguyen, et al., 2018) Unstained B. burgdorferi strain B31-A3 was applied to ensure accurate gating, in which the aggregated spirochetes were eliminated as described (Hart, Nguyen, et al., 2018) . Additionally, the spirochetes incubated with only the secondary antibody as control experiment to ascertain the specificity of primary antibody to bind to the cognate antigen. The mean fluorescence index of each sample was obtained from FlowJo software (Tree Star Inc., Ashland, OR) representing the surface production of the indicated proteins. Each standard deviation of mean value was no more than 7% of its mean value.
| Serum susceptibility assay
The serum susceptibility of B. burgdorferi was measured as described (Alitalo et al., 2001) . Briefly, triplicate samples of each strain were grown to mid-log phase and diluted to a final concentration of 5 × 10 6 bacteria per millilitre into BSK-II medium without rabbit serum, plus a final concentration of 40% human or quail serum or C3-depleted human serum (ComTech). We also included heatinactivated serum from these hosts, which was incubated at 55°C for 2 hr prior to incubation with spirochetes. Immediately after and 4 hr after incubation, an aliquot was taken from each replicate and counted by a Petroff-Hausser Counting Chamber (Hausser Scientific, Horsham, PA) using a Nikon Eclipse E600 dark-field microscope (Nikon, Melville, NY). The percentage of survival for B. burgdorferi was calculated using the number of mobile spirochetes at 4 hr post incubation normalised to that immediately after adding the serum.
| Mouse and quail infection experiments
Four-week-old female BALB/c mice or C3 −/− mice in a BALB/c background or C. coturnix quail were subcutaneously infected with 10 3 (for mouse infection) or 10 6 (for quail infection) of B. burgdorferi strains as described (Y. P. Lin et al., 2014) . The number of quail and mouse used in each experiment is described in respective figure legends.
The plasmid profiles and the presence of the shuttle vector of each of these B. burgdorferi strains were verified prior to infection as described (Purser & Norris, 2000) . Mice were sacrificed at 7 dpi to collect the blood and 7 or 14 dpi to collect the inoculation site of skin, tibiotarsal joints, bladder, and heart. Quail were sacrificed at 3 and 7 dpi to collect the blood, inoculation site of skin, liver, heart, and brain. Animal tissues were used to quantitatively evaluate the levels of colonization during infection (see Section 4.4). Note that quail blood and tissues were also incubated in BSK-II complete medium at 33°C for 4 weeks to cultivate spirochetes microscopically to verify the viability of spirochetes (Liveris et al., 2002) .
| Statistical analysis
Significant differences between samples were determined using the Kruskal-Wallis test with Dunn's multiple comparison or the MannWhitney test. A P value <0.05 was considered to be significant.
